Physician profile
Ulla Ule
NPI 1952391203
$383.57
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $33.41 · 2021: $11.92.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $125.00 | 2019 | |
| Merck Sharp & Dohme LLC | $51.69 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $36.66 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $30.64 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.27 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.10 | 2019 | |
| Celgene Corporation | $16.43 | 2019 | |
| Eusa Pharma (US) LLC | $16.30 | 2019 | |
| Daiichi Sankyo INC. | $15.50 | 2019 | |
| Eisai INC. | $14.42 | 2019 | |
| Amgen INC. | $13.01 | 2019 | |
| Clovis Oncology, INC. | $12.63 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ulla Ule listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.